CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?

Author:

Bartoló-Ibars Ariadna,Uribe-Herranz Mireia,Muñoz-Sánchez GuillermoORCID,Arnaldos-Pérez CristinaORCID,Ortiz-Maldonado Valentín,Urbano-Ispizua Álvaro,Pascal Mariona,Juan ManelORCID

Abstract

Allogenic hematopoietic stem cell transplantation (allo-HSCT) is one of the standard treatments for B-cell lymphoproliferative disorders; however, deep relapses are common after an allo-HSCT, and it is associated with poor prognosis. A successful approach to overcome these relapses is to exploit the body’s own immune system with chimeric antigen receptor (CAR) T-cells. These two approaches are potentially combinatorial for treating R/R B-cell lymphoproliferative disorders. Several clinical trials have described different scenarios in which allo-HSCT and CAR-T are successively combined. Further, for all transplanted patients, assessment of chimerism is important to evaluate the engraftment success. Nonetheless, for those patients who previously received an allo-HSCT there is no monitorization of chimerism before manufacturing CAR T-cells. In this review, we focus on allo-HSCT and CAR-T treatments and the different sources of T-cells for manufacturing CAR T-cells.

Funder

Fundación Bancaria Caixa d’Estalvis i Pensions de Barcelona

Instituto de Salud Carlos III

Ministry of Business and Knowledge of the Government of Catalonia and European Union's Horizon 2020

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference70 articles.

1. Diffuse Large B Cell Lymphoma;Padala,2021

2. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors

3. Chapter 104: Non-Hodgkin’ s Lymphoma;Jacobson,2021

4. Leukemia;Lynegar,2020

5. Current and future treatment strategies in chronic lymphocytic leukemia

Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3